Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T.
OBJECTIVE
To examine and compare properties of high-molarity contrast agent gadobutrol (Gadovist) and weakly protein-binding agent gadobenate-dimeglumine (MultiHance in dynamic susceptibility contrast (DSC) perfusion imaging at 3 T.


METHODS
Sixteen healthy volunteers underwent three separate examinations with contrast agent doses of 0.1 and 0.2 mmol/kg body weight (bw) gadobutrol and 0.1 mmol/kg bw gadobenate-dimeglumine. Maps of relative regional cerebral blood volume (rCBV) and blood flow (rCBF) were calculated using deconvolution based on singular value decomposition. Signal and concentration time curves, the concentration-to-noise ratio (SNR(c)), and gray matter (GM)-to-white matter (WM) rCBV and rCBF contrast and ratios were evaluated in a region of interest (ROI)-based analysis. Image quality of calculated parametric maps was assessed in direct visual comparison and with respect to suitability for diagnostic purposes.


RESULTS
The contrast agents displayed very similar results in the 0.1 mmol/kg examinations, both with respect to the quantitative evaluation parameters and in the qualitative assessment of the calculated parametric maps. Maps from 0.2 mmol/kg examinations were rated as being superior in quality, but with respect to diagnostic suitability all contrast agents and doses yielded images of sufficient quality.


CONCLUSIONS
At 3 T, a gadobutrol or gadobenate-dimeglumine dose of 0.1 mmol/kg is sufficient for DSC magnetic resonance imaging (MRI) perfusion assessment. At the used small injection volumes, the tissue concentration curve was determined only by the gadolinium (Gd) dosage in mmol/kg, and the T2* relaxation effects of the two agents can be considered to be nearly identical in the applied gradient-echo (GRE) sequence.
Thilmann
Oliver
O
Department of Medical Radiation Physics, Lund University, Lund, Sweden. Oliver.Thilmann@med.lu.se
Larsson
Elna-Marie
EM
Björkman-Burtscher
Isabella M
IM
Ståhlberg
Freddy
F
Wirestam
Ronnie
R
D000328:Adult; D001921:Brain / Q000033:anatomy & histology / Q000098:blood supply* / Q000378:metabolism / Q000502:physiology*; D001931:Brain Mapping / Q000379:methods; D002560:Cerebrovascular Circulation / Q000502:physiology*; D003287:Contrast Media / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D008970:Molecular Weight; D009419:Nerve Tissue Proteins / Q000378:metabolism; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000737:chemistry
D003287:Contrast Media; D009419:Nerve Tissue Proteins; D009942:Organometallic Compounds; C064572:gadobenic acid; C090600:gadobutrol; D008536:Meglumine